Top advances of the year: Neoadjuvant therapy in pancreatic cancer
Cancer · 01.05.2026 · 132 (9)
DOI: 10.1002/cncr.70431 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 02.05.2026. Verfasst von Jorge I Portuondo und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Recent phase 3 trials have generated clinically actionable data that help define neoadjuvant therapy for localized pancreatic ductal adenocarcinoma, while exposing the limitations of anatomic patient selection. Emerging evidence signals that the field is poised to transition toward biology‐driven, response‐adaptive frameworks.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Matthew H G Katz
Zitieren
APA
Portuondo, J. I., & Katz, M. H. G. (2026). Top advances of the year: Neoadjuvant therapy in pancreatic cancer. Cancer, 132(9). https://doi.org/10.1002/cncr.70431
Vancouver
Portuondo JI, Katz MHG. Top advances of the year: Neoadjuvant therapy in pancreatic cancer. Cancer. 2026;132(9). doi:10.1002/cncr.70431
BibTeX
@article{Portuondo2026,
author = {Portuondo, Jorge I and Katz, Matthew H G},
title = {Top advances of the year: Neoadjuvant therapy in pancreatic cancer},
journal = {Cancer},
year = {2026},
volume = {132},
number = {9},
doi = {10.1002/cncr.70431}
}
EUVIMED